Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/170234
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Montesdeoca, Nicolás | - |
dc.contributor.author | López, Marta | - |
dc.contributor.author | Ariza Piquer, Xavier | - |
dc.contributor.author | Herrero Rodríguez, Laura | - |
dc.contributor.author | Makowski, Kamil | - |
dc.date.accessioned | 2020-09-04T10:35:20Z | - |
dc.date.available | 2020-09-04T10:35:20Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 0892-6638 | - |
dc.identifier.uri | http://hdl.handle.net/2445/170234 | - |
dc.description.abstract | Cancer cells rely on several metabolic pathways such as lipid metabolism to meet the increase in energy demand, cell division, and growth and successfully adapt to challenging environments. Fatty acid synthesis is therefore commonly enhanced in many cancer cell lines. Thus, relevant efforts are being made by the scientific community to inhibit the enzymes involved in lipid metabolism to disrupt cancer cell proliferation. We review the rapidly expanding body of inhibitors that target lipid metabolism, their side effects, and current status in clinical trials as potential therapeutic approaches against cancer. We focus on their molecular, biochemical and structural properties, selectivity and effectiveness and discuss their potential role as antitumor drugs. Keywords: cancer drugs; lipid metabolism; lipogenic enzyme inhibitors. | - |
dc.format.extent | 27 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | The Federation of American Society of Experimental Biology | - |
dc.relation.isformatof | Versió preprint del document publicat a: https://doi.org/10.1096/fj.202000705R | - |
dc.relation.ispartof | The FASEB Journal , 2020, vol. 34, num. 9, p. 11355-11381 | - |
dc.relation.uri | https://doi.org/10.1096/fj.202000705R | - |
dc.rights | (c) The Federation of American Society of Experimental Biology, 2020 | - |
dc.source | Articles publicats en revistes (Bioquímica i Fisiologia) | - |
dc.subject.classification | Enzims | - |
dc.subject.classification | Metabolisme dels lípids | - |
dc.subject.classification | Medicaments antineoplàstics | - |
dc.subject.other | Enzymes | - |
dc.subject.other | Lipid metabolism | - |
dc.subject.other | Antineoplastic agents | - |
dc.title | Inhibitors of lipogenic enzymes as a potential therapy against cancer | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/submittedVersion | - |
dc.identifier.idgrec | 702851 | - |
dc.date.updated | 2020-09-04T10:35:21Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Bioquímica i Fisiologia) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
702851.pdf | 256.44 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.